GMP production of [
Automation
GMP
Gallium-68
Liver fibrosis
Plateled derived growth factor receptor β
Radiopharmaceuticals
Journal
Nuclear medicine and biology
ISSN: 1872-9614
Titre abrégé: Nucl Med Biol
Pays: United States
ID NLM: 9304420
Informations de publication
Date de publication:
Historique:
received:
17
06
2020
revised:
22
07
2020
accepted:
28
07
2020
pubmed:
18
8
2020
medline:
8
2
2022
entrez:
18
8
2020
Statut:
ppublish
Résumé
Early detection of liver fibrosis and monitoring response to treatment crucial for the management of patients are currently not feasible in clinical practice. Platelet derived growth factor receptor β (PDGFR-β) expression is regarded as a potential biomarker to determine the stages of fibrotic diseases including liver fibrosis. [ The active pharmaceutical ingredient starting material BOT5035 (GMP grade) was provided by BiOrion Technologies BV. The The GMP compliant automated production of [ The fully automated and GMP compliant production of [
Identifiants
pubmed: 32805638
pii: S0969-8051(20)30183-9
doi: 10.1016/j.nucmedbio.2020.07.009
pii:
doi:
Substances chimiques
Gallium Radioisotopes
0
Peptides, Cyclic
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
73-85Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosures Herman Steen and Guus van Scharrenburg are an employee of BiOrion Technologies BV. Otherwise, the authors have nothing to disclose.